Isomorphic Labs
Benjamin Rahemtulla is a Senior Research Investigator at Isomorphic Labs, focusing on AI applications in drug discovery since November 2024. Previously, Benjamin worked as an Associate Principal Scientist at Pharmaron from August 2019 to November 2024, contributing as a synthetic and medicinal chemist across various client programs and achieving milestones in candidate nominations. Prior experience includes a postdoctoral role in medicinal chemistry at Theravance Biopharma US, Inc., where work centered on kinase inhibitor projects, and a DPhil in organic chemistry from the University of Oxford, which involved research in phase-transfer catalysis. Benjamin also completed a CASE placement at GSK and a Year In Industry placement at Praxair earlier in their academic career, culminating in a Master of Chemistry from the University of Oxford in 2014 and a Bachelor’s from Magdalen College School.
This person is not in any teams
Isomorphic Labs
7 followers
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.